CLARITY PHARMACEUTICALS LTD DISCLOSURECurrent Reports (8-K / ad hoc)

Preliminary Final Report

E: [email protected] W: www.claritypharmaceuticals.com ACN: 143 005 341 T: +61 (0)2 9209 4037 CLARITY PHARMACEUTICALS LIMITED ASX MEDIA RELEASE 27 August 2026 Appendix 4E Preliminary Final Report – 30 June 2026 Clarity Pharmaceuticals Ltd (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company focused on the treatment of serious diseases, is pleased to announce it has released its Appendix 4E: Preliminary Final Report for the year ending 30 June 2026. The Appendix 4E is attached to this release. This release is authorised by the board of directors of Clarity. For more information, please contact: Dr Alan Taylor Lisa Sadetskaya Executive Chairman Director, Corporate Communications [email protected] [email protected] About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer. www.claritypharmaceuticals.com/ For personal use only Appendix 4E Preliminary final report for the year ended 30 June 2026 1. Company details Name of entity: Clarity Pharmaceuticals Ltd ABN: 36143005341 Reporting period: Year ended 30 June 2026 Previous period: Year ended 30 June 2025 2. Results for announcement to the market $'000 Revenue from ordinary activities up 68% to 8,004 Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd up 67% to (107,242) Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd up 67% to (107,242) Dividends There were no dividends paid, recommended, or declared during the current financial period. Comments The loss for the consolidated entity after providing for income tax amounted to $107,421,282. Further comment on the ‘Review of operations’ is detailed in the Director’s Report which is part of the Annual Report. 3. Net tangible assets Reporting period Cents Previous period Cents Net tangible assets per ordinary security 49.9 28.1 4. Control gained over entities Not applicable. 5. Loss of con